Rubraca sheds positive light for PARP inhibitors in endometrial cancer

On 18 March 2024, positive Phase II results of Clovis Oncology’s Rubraca were presented at the Society of Gynecologic Oncology conference, where Rubraca was evaluated as maintenance therapy in patients with metastatic and recurrent endometrial cancer, following one or two prior lines of systemic therapy.